Crinecerfont for Congenital Adrenal Hyperplasia in Young Children
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
- Age
- 3 Months – 47 Months
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 20 (estimated)
- Sponsor
- Neurocrine Switzerland GmbH · Industry
This trial is looking for young children aged 3 months to less than 4 years with a specific type of adrenal condition called congenital adrenal hyperplasia (CAH). Participants will be given crinecerfont to see how safe it is and how well it is tolerated.
You may be able to join if
- I have been diagnosed with classic CAH due to 21-hydroxylase deficiency.
- I have been on hydrocortisone treatment for at least 3 months.
- I weigh at least 4.5 kilograms.
- I have normal newborn screening results except for elevated 17-OHP.
You may not be able to join if
- I have been diagnosed with another form of classic CAH.
- I have another condition that needs daily steroid therapy.
- I have any other serious medical condition or chronic disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Loading trial locations…